Jena and und Allschwil, February 15, 2011 — Starting now, the spectrophotometers of Analytik Jena's SPECORD® PLUS series will be complementing the product range of the Swiss company SOTAX, a leading solutions provider in the pharmaceutical industry.

With this mutually beneficial cooperation, Analytik Jena AG is taking the chance to embrace new opportunities and new market potential in the pharmaceutical industry worldwide. For SOTAX AG, the partnership with the Jena-based high tech company is an opportunity to strengthen its position as a leading dissolution systems provider.

The UV/Vis spectrophotometers of the SPECORD® PLUS series can easily be coupled with the SOTAX online dissolution systems. The photometers are completely integrated into the system software. This combination offers a sophisticated automatic dissolution test system for online UV/Vis measurements. In the pharmaceutical industry, dissolution devices are used for testing drugs. The devices simulate the dissolution of agents to be tested in the body and provide both qualitative and quantitative information.

In the pharmaceutical industry, SPECORD® PLUS can also be used as a stand-alone solution for photometric analysis. The control and analysis software WinASpect® PLUS quickly provides valid results. Thanks to the 8-cell and 2x 8-cell changers, the degree of automation is very high.

The SPECORD® PLUS instruments conform to all international pharmacopoeia and are certified for installation qualification and operational qualification. They thus fulfill the strict requirements for equipment qualification in the pharmaceutical industry.

Thomas Pfammatter, SOTAX CEO: "Since we've installed Analytik Jena's SPECORD® PLUS photometer with our SOTAX instruments, it has already proven extremely precise, robust and reliable. Equipped with an 2x 8-cell changer it is the ideal photometer for a double UV online dissolution system. Our customers can now benefit from the complete package: SOTAX offers and supports the integrated configuration with a SPECORD® PLUS photometer (qualification, repair, maintenance).”

Press contacts:
Analytik Jena AG
Dana Schmidt, press spokeswoman
phone +49 36 41 77-92 81
fax  +49 36 41  77-99 88

Sabine Eberl, Analytical Instrumentation
E-mail: s.eberl@analytik-jena.com

SOTAX AG
Petra Silbereisen
E-mail: petra.silbereisen@sotax.com

About Analytik Jena AG:
Founded in 1990 as a sales and service company for analytical technology, Analytik Jena AG has established itself as one of the leading manufacturers of analytical and bioanalytical systems for industrial and scientific applications. Since the birth of the company, its success has been based on its sustainable strategy of combining the long-standing innovative strength and high-end products of Jena/Thuringia with the growth potential of international markets. In the three symbiotically related business units for specialised instruments “Analytical Instrumentation”, “Life Science" and “Optics”, Analytik Jena offers analytical, bioanalytical and optical products in a modern and popular segment of technology. For more information, visit www.analytik-jena.com.

About SOTAX AG:
SOTAX is a global leader in providing innovative solutions for pharmaceutical testing. The company offers high-quality dissolution testing systems, composite assay and content uniformity workstations, and physical tablet testing instruments as well as associated technical and application services. Integrated in 2008, the Zymark® brand completes the SOTAX product lines and expertise in the automation segment. SOTAX also offers SPS Pharma Services, a contract research lab dedicated to research and method development (CRO). More information on www.sotax.com.

• Revenue and EBIT in line with expectations
• Net profit and EPS increased by 3.7 % or by 13.6 %
• Operating cashflow up 33.4 % year-on-year

Jena (Germany), February 14, 2012 — Analytik Jena AG (Prime Standard: AJA, ISIN: DE0005213508) has made a good start into the financial year 2011/2012. After three months consolidated revenue of EUR 23.2 m (previous year: EUR 23.7 m) was achieved and remained largely stable year-on-year. Overall, the Group generated a net profit for the period of EUR 1.5 m. Earnings per share were EUR 0.25 (previous year: EUR 0.22).

"We are satisfied with the results achieved in the first quarter. Overall, we are in line with our expectations. Both regarding revenue and earnings, without large-scale orders we were successfull to build on a strong quarter last year", said Klaus Berka, CEO of Analytik Jena AG. "We expect to reach and to exceed previous-year level already in the second quarter."

Revenue Development and Segments

In what is by far the most important export market for Analytik Jena, sales in Asia again rose in double digits, by 15.4 %. Over here, the Group generated overall revenue of EUR 7.8 m (previous year: EUR 6.8 m). In the America sales region revenue totaled EUR 2.0 m (previous year: EUR 1.6 m). On its home market, Analytik Jena posted sales of EUR 6.9 m (previous year: EUR 8.1 m) and in Europe EUR 5.8 m (previous year: EUR 6.6 m). After three months, due to the regional shift of sales to Asia, the export ratio was 70.1 % (previous year: 66.0 %).

The biggest segment, Analytical Instrumentation was down only 2.7 % year-on-year with sales of EUR 14.1 m. Analytik Jena anticipates the segment will compensate for the decline in sales in the third quarter and on a whole-year basis again exceed the previous-year sales level.

Despite good end-of-year business in 2011, in the first quarter of 2011/2012 Life Science sales also declined slightly year-on-year, by 0.9 %. This is due particularly to declining sales at CyBio AG (consolidated in this segment) not reaching the strong level of the previous year. After three months, revenue in Life Science segment totaled EUR 7.9 m (previous year: EUR 8.0 m).

In the reporting period, in the Optics consumer segment Analytik Jena generated EUR 1.1 m (previous year: EUR 1.2 m), 7.7 % less than in the previous year. In the second quarter, the segment will again be able to grow through the extension of the service portfolio as OEM vendor. Analytik Jena was successful in acquiring an additional order volume of EUR 1.1 m for special optical products and components.

Earnings

After three months in the current financial year the Group posted net profit for the period of EUR 1.5 m (previous year: EUR 1.4 m). That corresponds to an increase of 3.7 % compared to last year's period. Earnings per share were at EUR 0.25 (previous year: EUR 0.22). The Company benefited especially from the development of the USD at the end of the quarter. Correspondingly, the financial result and EBT developed positively. The Group posted total EBT of EUR 2.1 m (previous year: EUR 2.0 m), an upturn of 3.7 %. EBITDA fell by 9.1 % to EUR 2.9 m (previous year: EUR 3.2 m). In the past quarter, the Group posted an operating profit (EBIT) of EUR 1.9 m (previous year: EUR 2.2 m), 15.9 % down year-on-year. The Company achieved an EBIT margin of 8.2 % compared with 9.5 % in the same quarter of the previous year.

Changes in Statement of Financial Position

The Group’s total assets remained nearly constant at EUR 84.1 m as of December 31, 2011. This compared with EUR 83.6 m (September 30, 2011). In the reporting period, Analytik Jena reported equity of EUR 39.8 m (September 30, 2011: EUR 38.6 m), representing an increase of 3.1 % and a rise in the equity ratio from 46.1 % as of September 30, 2011 to 47.3 % as of December 31, 2011. Cash and cash equivalents totaled EUR 6.0 m as of the end of the reporting period (September 30, 2011: EUR 5.5 m). This corresponds to a year-on-year increase of 9.1 % and is primarily the result of the 33.4 % rise in operating cashflow (EUR 1.7 m after three months, previous year: EUR 1.3 m).

Human Resources

As of the balance sheet date December 31, 2011, the Group employed 807 staff, including 39 trainees (previous year: 799 employees, including 46 trainees).

Outlook

For the rest of the financial year, Analytik Jena anticipates that the conditions affecting its business activities will remain largely the same. The Company expects to achieve profitable cross-segment growth with its entire portfolio in the current financial year 2011/2012.

For the second quarter, the Company anticipates sales will remain stable and results to be good.

As usual, Analytik Jena will announce its outlook for the entire financial year at the Annual General Meeting on April 24, 2012.

Further Information

The full financial report can be accessed athttp://berichte.analytik-jena.de/3-MonthReport_1112.pdf.

Jena, February 8, 2012 – Hereby Analytik Jena AG (Prime Standard: AJA, ISIN: DE0005213508) announced that the cash capital increase resolved on January 26, 2012 was entered in the commercial register today.

As part of the capital increase, 470,000 new no-par value bearer shares were placed at a subscription price of EUR 10.48 per share. The Company’s share capital was thus increased from EUR 5,235,465.00 to EUR 5,705,465.00. The shares were fully subscribed by Beteiligungsfonds Thüringer Industriebeteiligungs-GmbH & Co. KG (TIB) managed by bm-t beteilungsmanagement thüringen gmbh (bm-t), Erfurt. As a result its stake in Analytik Jena moved up to 17.79 %.

With the entry of the capital increase into the commercial register at the Registry Court of Jena the new shares are issued and are entitled to profits as of October 1, 2011.

Contact:
Dana Schmidt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Phone +49 (0) 36 41 77 92 81
E-mail: ir@analytik-jena.de

Jena (Germany), January 26, 2012 - On January 25, 2012, the Executive Board of Analytik Jena AG (Prime Standard: AJA, ISIN: DE0005213508) utilized the authorization granted by the Annual General Meeting on March 19, 2009 and resolved a cash capital increase from authorized capital. The Super-visory Board of Analytik Jena today approved the capital increase.

The share capital of the Company from the current figure of EUR 5,235,465.00 will be increased by partially utilizing the Authorized Capital by issuing 470,000 new no-par value bearer shares at a sub-scription price of EUR 10.480 per share with shareholders' subscription rights disapplied. The sub-scription price corresponds to the volume-weighted average price on the last five trading days (Xetra) less a discount of 3 %. The new shares will be fully subscribed by the Thüringer Industriebeteiligungs-GmbH & Co. KG (TIB), an investment fund managed by the bm-t beteilungsmanagement thüringen gmbh (bm-t), Erfurt. bm-t already holds an interest in Analytik Jena AG of 10.41 % and thus increases its stake to 17.79 %.

Analytik Jena AG intends to use the proceeds from the capital increase to finance the strategic devel-opment of the Company.

Analytik Jena has commissioned IKB Deutsche Industriebank AG to manage the transaction.

"Following a successful 2010/2011 financial year, we are looking to continue Analytik Jena's growth path. The proceeds from the capital increase will be used for the further expansion of our business, particularly through additions to our portfolio that offer significant synergy effects. However, we cannot make any concrete statements at present," commented Klaus Berka, CEO of Analytik Jena AG. "We are pleased that, with its investment, bm-t is backing Analytik Jena's growth policy and strongly positioning itself as a long-term strategic investor."

Contact:
Dana Schmidt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Phone: +49 (0) 36 41 77 92 81
E-mail: ir@analytik-jena.com

• Sales record based on sound business development
• Operating result considerably higher than previous year
• Result influenced by extraordinary tax expenses relating to other periods
• Growth expected for financial year 2011/2012 with a quieter first quarter

Jena, December 15, 2011 — In the past financial year 2010/2011, the Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) was again able to increase its revenue significantly. Overall, the Group generated sales of EUR 86.3 m (previous year: EUR 80.2 m), a 7.6 % increase on the previous year. In the process, Analytik Jena again surpassed the record achieved in the previous year. Operating profit (EBIT) amounted to EUR 5.0 m (previous year: EUR 3.1 m), up 59.3 % year-on-year.

"After the previous financial year was basically characterized by one-time effects, we succeeded in growing our operating result again.“ commented Klaus Berka, CEO of Analytik Jena AG. “We could again increase in sales and exceed the record level of sales we set last year. We achieved this due to the outstanding development in our largest business area, Analytical Instrumentation that managed to grow its revenue by 11.3 % last year based on its traditionally strong export operations."

Revenue Development and Segments

From a strong competitive position in the optical spectroscopy sector, the Analytical Instrumentation business unit was again able to win market share in the reporting period and increase its revenue. Analytik Jena closed the financial year in this segment with revenue of EUR 53.2 m (previous year: EUR 47.8 m), representing a gain of 11.3 %. Life Science business unit recorded sales of EUR 28.3 m (previous year: EUR 27.5 m), 2.7 % higher than in the previous year. The Optics segment was able to halt a three-year downward slide caused by economic conditions, nearly matching the previous year’s level. Revenue in financial year 2010/2011 totaled EUR 4.8 m (previous year: EUR 4.9 m). That equates to a slight decrease of 1.1 %.

Financial Position and Results of Operations

The Group ended the full financial year of 2010/2011 with earnings before interest, taxes, depreciation, and amortization (EBITDA) of EUR 8.8 m (previous year: EUR 6.7 m) and operating profit of EUR 5.0 m (previous year: EUR 3.1 m). In the process, Analytik Jena recorded increases in EBITDA of 31.0 % and EBIT of 59.3 %. Once again, the Company achieved a double-digit EBITDA margin of 10.2 % (previous year: 8.4 %). The EBIT margin was 5.8 % compared with 3.9 % in the previous year. Therefore, Analytik Jena performed much better on an operating basis than in the previous year.

The Group’s tax expense totaled EUR 2.6 m (previous year: EUR 1.1 m). Of this amount, EUR 0.8 m accrues to current actual tax expense and deferred tax income. This corresponds to a tax rate of 27.6 %. In addition, tax expense of EUR 1.8 m includes non-period tax expense resulting from the agreement with the Gera tax office in financial year 2010/2011. The consolidated net profit for the year fell compared with the amount for the previous year by 90.7 % and totaled EUR 0.2 m (previous year: EUR 2.1 m). For the shareholders of Analytik Jena AG both basic and diluted earnings per share amounted to EUR -0.03 (previous year: EUR 0.34).

The Group’s total assets as of the balance sheet date on September 30, 2011 remained similar to the previous year’s level and amounted to EUR 83.6 m.

Human Resources

As of September 30, 2011, the Group had a total of 802 employees, including 38 interns (previous year: 796 employees, including 49 interns), or 0.8 % more than as of the previous balance sheet date.

Outlook

With respect to the financial year 2011/2012, Analytik Jena expects that it will be able to achieve further increases in revenue and earnings in all three business units. The Company expects that revenue will be distributed relatively evenly over the quarters and that no major disruptions will be caused by large projects.

"The Company plans further investments in the expansion of the Thuringian manufacturing site in Langewiesen amounting to about EUR 0.7 and remains clearly committed to the manufacturing site Germany. Further important milestones are the market launch of some product innovations that are meant to contribute to the stable growth of the segments. We especially expect good impetus for the expansion of our business from the prestigious international trade fairs IWA in Nuremberg at the beginning of March concerning Optics and the 'analytica' in April in Munich concerning both segments Analytical Instrumentation and Life Science." Berka added.

The full financial report can be accessed at http://berichte.analytik-jena.de/AnnualReport1011.pdf .

Jena/Yokohama, December 13, 2011 — Analytik Jena AG is expanding its product range in Japan, the world’s third-largest market for analytical measurement technology. As part of a sales partnership with Japanese company Techno-X, the Japanese subsidiary of the Jena-based Group will in future offer instruments for X-ray fluorescence spectroscopy, a method of determining the concentrations of elements in liquid and solid samples in cases where, unlike with other processes, the sample must not be destroyed for or during the analysis.

"With the products of our new partner, Techno-X, we are expanding our product portfolio with the addition of X-ray fluorescence equipment, which addresses what is a global growth market. The initial plan is to operate only on the Japanese market, where these products are already familiar," comments Klaus Berka, CEO of Analytik Jena AG. "Our goal is to achieve sales of EUR 1.5 to 2.0 million in the current financial year alone."

The Japanese company Techno-X was established in 2009 and employs 25 people. As part of the sales cooperation, Analytik Jena is fully incorporating the sales team of its new partner into the sales structures of its Japanese subsidiary.

"We hope to strengthen our market position in Japan by combining our partner’s technological expertise in the field of X-ray fluorescence spectroscopy with the sales skills of Analytik Jena. In the future, Techno-X will be able to dedicate greater focus to research and development," continues Berka.

X-ray fluorescence spectrometers are used by Techno-X for such applications as on-site analysis — for example, in the field of petrochemistry to analyze sulfur and chlorine — or in food inspection laboratories for analyzing the cadmium content of rice, for instance. In X-ray fluorescence spectroscopy, the samples are exposed to practically non-destructive X-rays, which means that the sample can be analyzed both qualitatively and quantitatively in terms of its chemical composition.